2 results
Search Results
Now showing 1 - 2 of 2
Other Current Induction Therapy Strategies and Anti-T Lymphocyte Globulin Usage in Kidney Transplantation: Consensus-Based Recommendations by a Turkish Expert Panel(Aves, 2024) Çakır, Ülkem; Dinçkan, Ayhan; Karadoğan, Nayim; Keven, Kenan; Koçak, Hüseyin; Koç, Serkan Kubilay; Yıldız, Alaattin; Turkmen, Aydin; Töz, Hüseyin; Sezer, SirenThis advisory committee convened to review national and global kidney transplantation dynamics and provide recom- mendations on the use of anti-T lymphocyte globulin (ATLG) for prevention and treatment of rejection after allogeneic kidney transplantation. A critical evaluation of 6 relevant articles released up to October 2022 was performed to reveal their importance in clinical practice. Additionally, 27 key questions on the indication, dosage of ATLG, and risk stratification were used for the Delphi technique with 8 members of the Turkish Society of Nephrology including 5 kidney transplanta- tion (KTx) subcommittee members and a surgeon experienced in solid organ transplantation. The committee declared that Türkiye had great potential in KTx; however, increase in transplantation would be possible in the case of raise in the deceased donor transplantation. As a consensus, ATLG was strongly recommended for induction and rejection treatment. Also, committee members recommended the safe dosage range in steroid resistant acute rejection as 2.5-3 mg/kg daily for 5-7 days, and the median of preferred dosage in induction sounded as 2-2.5 mg/kg daily for 3 days in intermediate risk state. Additionally, post-transplant infection and malignancy cases due to immunosuppression were much rarely encoun- tered than they were in the past.Article Evaluation of Covid-19 Cases Who Received Immunosuppressive Therapy at a Tertiary Care Hospital(Doc design informatics Co Ltd, 2022) Sayar, Merve Sefa; Acar, Ali; Bulut, Dilek; Celik, Sebahattin; Oguz, EminObjective: Immunosuppressive drugs are included in the treatment protocols of severe COVID-19 cases that may present with cytokine storm. In this study, we aimed to examine the characteristics of COVID-19 patients who received immunosuppressive therapy Methods: Patients diagnosed with COVID-19 and followed in the quarantine wards of our hospital between 01.03.2020-24.05.2020 were included in the study. Patient information was obtained retrospectively from patient files and discharge reports, and 263 COVID-19 patients-aged 18 and over-were included in the study. Results: The median age of the patients who received immunosuppressive therapy was 60.74 +/- 1.96, and 39.6% of them were women. The average symptom duration of the patients examined in the study at the time of admission to the hospital was 4.59 +/- 0.29 days. There was a significant difference in age, lymphocyte count, neutrophil/lymphocyte ratio, C-reactive protein, ferritin, D-Dimer, blood oxygen saturation, fever after antiviral therapy, qSOFA score, and total hospital stay between the two groups that received and did not receive immunosuppressive therapy (p<0.05). The need for immunosuppressive therapy increased 15.9 times over the age of 40, 15.6 times in the presence of diffuse involvement on thoracic CT, 6.6 times in the presence of chronic disease, 2.7 times in the presence of thrombocytopenia, and 1.7 times in the presence of lymphopenia (p <0.05).Conclusions: We observed that patients whose immunosuppressive therapy was added to their treatment protocols were admitted to the hospital later than others, had more prevalent involvement in thorax CT, high acute phase reactants, low SPO2, and more than one underlying disease.
